{"id":"hypoglycemic-agents-metformin","safety":{"commonSideEffects":[{"rate":"20–30","effect":"Gastrointestinal disturbance (nausea, diarrhea, abdominal discomfort)"},{"rate":"3–5","effect":"Metallic taste"},{"rate":"10–30","effect":"Vitamin B12 deficiency"},{"rate":"<0.1","effect":"Lactic acidosis (rare, in renal impairment)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Metformin is a biguanide that primarily works by decreasing gluconeogenesis in the liver and enhancing glucose uptake and utilization in muscle and adipose tissue. It does not stimulate insulin secretion, making it weight-neutral and useful in combination with other agents. The drug may also improve insulin sensitivity through activation of AMP-activated protein kinase (AMPK) and modulation of mitochondrial function.","oneSentence":"Metformin reduces hepatic glucose production and improves insulin sensitivity in peripheral tissues, thereby lowering blood glucose levels in type 2 diabetes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:47:55.083Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Prediabetes (off-label or prevention studies)"}]},"trialDetails":[{"nctId":"NCT05013112","phase":"NA","title":"Ameliorating Metabolic Profiling After Kidney Transplantation (AMPKT)","status":"COMPLETED","sponsor":"West China Hospital","startDate":"2023-01-01","conditions":"Kidney Transplantation, Metabolic Disorder, Metformin","enrollment":105},{"nctId":"NCT07436182","phase":"PHASE4","title":"Mitochondrial Redox Modulation in Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Trial Comparing Imeglimin vs. Metformin Monotherapy","status":"NOT_YET_RECRUITING","sponsor":"Mansoura University","startDate":"2026-03-01","conditions":"Mitochondria, Metformin","enrollment":176},{"nctId":"NCT04416269","phase":"PHASE4","title":"Oral Anti Diabetic Agents in the Hospital","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2020-08-07","conditions":"Diabetes Mellitus","enrollment":255},{"nctId":"NCT07173712","phase":"PHASE4","title":"Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Yanbing Li","startDate":"2026-03-15","conditions":"Type 2 Diabetes","enrollment":324},{"nctId":"NCT07374328","phase":"PHASE1, PHASE2","title":"Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2025-06-01","conditions":"Type 2 Diabetes","enrollment":240},{"nctId":"NCT07309094","phase":"","title":"Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD","status":"RECRUITING","sponsor":"Cardenal Herrera University","startDate":"2023-09-15","conditions":"Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Chronic Kidney Disease Stage 1","enrollment":250},{"nctId":"NCT07057479","phase":"PHASE3","title":"Phase III Trial of SGLT2 Inhibitor and Thiazolidinedione Fixed-Dose Combination vs. Monotherapy in Type 2 Diabetes Patients on Metformin","status":"WITHDRAWN","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2026-09","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":""},{"nctId":"NCT07272109","phase":"PHASE3","title":"Active Anti-diabetic Treatment Plus Chemotherapy for Pancreatic Cancer Related Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-01-01","conditions":"Pancreatic Cancer","enrollment":210},{"nctId":"NCT07279909","phase":"PHASE3","title":"Phase-III Clinical Studies on Poly Herbal Anti-Diabetic Formulation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hamdard University","startDate":"2024-03-09","conditions":"Diabetes Type 2, Diabetes Mellitus, Experimental, HbA1c","enrollment":500},{"nctId":"NCT05220917","phase":"","title":"Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-08-01","conditions":"Cardiovascular Events, Type2 Diabetes, Renal Disease","enrollment":781430},{"nctId":"NCT07244003","phase":"PHASE4","title":"Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control","status":"RECRUITING","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","startDate":"2025-03-29","conditions":"T2DM (Type 2 Diabetes Mellitus)","enrollment":430},{"nctId":"NCT07209527","phase":"EARLY_PHASE1","title":"Truway Diagnostic Tools in Primary Care","status":"ENROLLING_BY_INVITATION","sponsor":"Truway Health, Inc.","startDate":"2025-10-01","conditions":"Chronic Disease, Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight, Hypertension","enrollment":200},{"nctId":"NCT04826692","phase":"PHASE3","title":"TEsting METformin Against Cognitive Decline in HD","status":"COMPLETED","sponsor":"Instituto de Investigacion Sanitaria La Fe","startDate":"2022-04-11","conditions":"Huntington Disease","enrollment":60},{"nctId":"NCT01471808","phase":"PHASE4","title":"Effects of Different Early Intensive Therapies on Long-term β-cell Function","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2011-10","conditions":"Diabetes Mellitus, Type 2","enrollment":264},{"nctId":"NCT05413369","phase":"PHASE3","title":"iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2022-07-07","conditions":"Type 2 Diabetes Mellitus","enrollment":582},{"nctId":"NCT07074379","phase":"NA","title":"Endotherapy and/or Extracorporeal Shockwave Lithotripsy for Painless Chronic Pancreatitis","status":"RECRUITING","sponsor":"Changhai Hospital","startDate":"2025-07-21","conditions":"Painless Chronic Pancreatitis","enrollment":126},{"nctId":"NCT06649773","phase":"PHASE3","title":"The Experiment of Noiiglutide Injection in Type 2 Diabetes Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-10-25","conditions":"Type 2 Diabetes","enrollment":137},{"nctId":"NCT06846138","phase":"NA","title":"Enhancing the Efficacy and Tolerability of Metformin by add-on Polyherbal Formulation: a Gut Microbiome Study","status":"ENROLLING_BY_INVITATION","sponsor":"Pauls Stradins Clinical University Hospital","startDate":"2025-03-01","conditions":"Diabetes Mellitus Type 2","enrollment":66},{"nctId":"NCT05966792","phase":"NA","title":"SGLT2 Inhibitors in Treating Patients With PCOS","status":"ENROLLING_BY_INVITATION","sponsor":"Shanghai 10th People's Hospital","startDate":"2023-11-10","conditions":"Polycystic Ovary Syndrome","enrollment":80},{"nctId":"NCT04841096","phase":"PHASE3","title":"Oral Combination of Glimepiride/Vildagliptin/Metformin in Patients With T2D and Dual Treatment Failure","status":"COMPLETED","sponsor":"Laboratorios Silanes S.A. de C.V.","startDate":"2023-03-21","conditions":"Type 2 Diabetes","enrollment":162},{"nctId":"NCT06932874","phase":"PHASE4","title":"Metformin Hydrochloride Sustained-release Tablets (Ⅲ) in Patients With Type 2 Diabetes Mellitus Complicated With Coronary Heart Disease","status":"RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2025-03-04","conditions":"Atherosclerotic Heart Disease, Type 2 Diabetes","enrollment":356},{"nctId":"NCT03464045","phase":"","title":"Empa PASS on Urinary Tract Malignancies","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2016-11-16","conditions":"Diabetes Mellitus, Type 2","enrollment":344995},{"nctId":"NCT06862739","phase":"PHASE4","title":"Glycemic Control with Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination","status":"NOT_YET_RECRUITING","sponsor":"Nabiqasim Industries (Pvt) Ltd","startDate":"2025-04","conditions":"Diabetes Mellitus, Type 2 DM","enrollment":800},{"nctId":"NCT04409795","phase":"PHASE2, PHASE3","title":"Oral Hypoglycemic Therapy for Monogenic Variant Carriers of the Joslin Medalist Study","status":"COMPLETED","sponsor":"Joslin Diabetes Center","startDate":"2021-08-26","conditions":"Type 1 Diabetes, Monogenic Diabetes","enrollment":3},{"nctId":"NCT06838286","phase":"","title":"Korean Study on Safety and Effectiveness of OAD Triple Therapy in Type 2 Diabetes","status":"RECRUITING","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2024-03-16","conditions":"Diabetes Mellitus, Type 2","enrollment":10000},{"nctId":"NCT04114136","phase":"PHASE2","title":"Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies","status":"RECRUITING","sponsor":"Dan Zandberg","startDate":"2020-09-14","conditions":"Melanoma, NSCLC, Hepatocellular Carcinoma","enrollment":72},{"nctId":"NCT06806345","phase":"PHASE1, PHASE2","title":"Hyperbaric Oxygen Therapy on Insulin Resistance in Postmenopause","status":"RECRUITING","sponsor":"Cairo University","startDate":"2025-01-28","conditions":"Insulin Resistance Syndrome","enrollment":40},{"nctId":"NCT06762223","phase":"PHASE4","title":"Henagliflozin on Liver Fibrosis in Patients with MASLD and T2DM","status":"NOT_YET_RECRUITING","sponsor":"Xiqiao Zhou","startDate":"2024-12-31","conditions":"Metabolic Dysfunction-associated Steatotic Liver Disease, Type 2 Diabetes Mellitus","enrollment":190},{"nctId":"NCT06611904","phase":"NA","title":"The Effect of Combined Dulaglutide and Dapagliflozin Treatment vs DPP-4 Inhibitors in Endothelial and Vascular Function in Patients With Type 2 Diabetes Mellitus and Albuminuria","status":"ACTIVE_NOT_RECRUITING","sponsor":"Attikon Hospital","startDate":"2018-02-01","conditions":"Urine Albumin (UAlb), Glycocalyx, Arterial Stiffness","enrollment":60},{"nctId":"NCT06570980","phase":"","title":"Comparative Analysis of Cost-effectiveness Between Sulfonylureas and DPP4 Inhibitors in Combination With Metformin in Treatment of Type 2 Diabetic Patients : A Retrospective, Observational Study.","status":"RECRUITING","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2023-08-25","conditions":"Type 2 Diabetes Mellitus (T2DM), Cost-effectiveness, Sulfonylureas, DPP4 Inhibitors, Metformin","enrollment":200},{"nctId":"NCT06449235","phase":"PHASE4","title":"Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh","status":"NOT_YET_RECRUITING","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","startDate":"2024-09","conditions":"Type2diabetes","enrollment":938},{"nctId":"NCT05284344","phase":"","title":"The Impact of Glucotoxicity on Gastric Emptying in Chinese Patients With Newly Diagnosed Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Adelaide","startDate":"2021-01-24","conditions":"Type 2 Diabetes","enrollment":78},{"nctId":"NCT05162014","phase":"","title":"To Assess the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes Mellitus Treated With Empagliflozin","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2021-12-20","conditions":"Diabetes Mellitus, Type 2","enrollment":494679},{"nctId":"NCT06370247","phase":"NA","title":"First-time Usage of SGLT2 Inhibitors in Type 2 Diabetic Patients Who Are Fasting During Ramadan: Safety and Efficacy","status":"COMPLETED","sponsor":"Sohag University","startDate":"2023-04-25","conditions":"SGLT2 Inhibitors, First Time Use, Type2 Diabetes, Fasting in Ramadan","enrollment":60},{"nctId":"NCT05505994","phase":"PHASE3","title":"The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on Metformin","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2022-09-28","conditions":"Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders","enrollment":340},{"nctId":"NCT03700801","phase":"PHASE4","title":"Study of Efficacy, Weight Control, and Safety in Newly-diagnosed Type 2 Diabetes With Different Antidiabetic Therapy","status":"COMPLETED","sponsor":"Zhujiang Hospital","startDate":"2018-10-01","conditions":"Type 2 Diabetes Mellitus","enrollment":130},{"nctId":"NCT06218342","phase":"PHASE4","title":"Henagliflozin in Relieving Type 2 Diabetes With Non-alcoholic Fatty Liver Disease","status":"UNKNOWN","sponsor":"Sir Run Run Shaw Hospital","startDate":"2024-02-15","conditions":"Type 2 Diabetes, Non-Alcoholic Fatty Liver Disease","enrollment":156},{"nctId":"NCT06203275","phase":"PHASE3","title":"The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"aya ramadan ashmawy sarhan","startDate":"2024-01","conditions":"Diabetes Mellitus, Type 2","enrollment":44},{"nctId":"NCT06164535","phase":"PHASE4","title":"The Effects of DPPIs on Cognitive Function of Diabetic Patients","status":"UNKNOWN","sponsor":"Beni-Suef University","startDate":"2023-12-30","conditions":"Cognitive Impairment","enrollment":105},{"nctId":"NCT06135584","phase":"NA","title":"Study on MAFLD-related Cirrhosis Prevention and Treatment Strategies","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Hospital of Hangzhou Normal University","startDate":"2023-11-18","conditions":"Metabolic Dysfunction-associated Fatty Liver Disease, Cirrhosis","enrollment":1000},{"nctId":"NCT03921242","phase":"","title":"Comparative Effectiveness of Metformin for Type 2 Diabetes With Chronic Kidney Disease","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2019-08-01","conditions":"Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic","enrollment":4888},{"nctId":"NCT05366868","phase":"PHASE4","title":"Durable Effect of Imeglimin on the Glycemic Control in Patients With Type 2 Diabetes Mellitus","status":"RECRUITING","sponsor":"National Center for Global Health and Medicine, Japan","startDate":"2022-05-26","conditions":"Diabetes Mellitus, Type 2","enrollment":567},{"nctId":"NCT06041399","phase":"PHASE4","title":"The Effect of Related Blood Markers on Diabetic Peripheral Neuropathy","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2012-02-01","conditions":"Diabetic Peripheral Neuropathy","enrollment":1400},{"nctId":"NCT05164523","phase":"","title":"The Effect of SGLT2 Inhibitors on Heart Rate Variability and BDNF Levels in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Goztepe Training and Research Hospital","startDate":"2021-03-01","conditions":"Type 2 Diabetes, Heart Rate Variability","enrollment":64},{"nctId":"NCT03877406","phase":"PHASE4","title":"Effect of Empagliflozin on Body Composition and Ketones","status":"UNKNOWN","sponsor":"Seoul National University Bundang Hospital","startDate":"2018-08-01","conditions":"Diabetes Mellitus, Fat; Intolerance, Pancreas","enrollment":200},{"nctId":"NCT05822674","phase":"","title":"Variable Effects of Anti-diabetics on Stress Hyperglycemia Ratio","status":"COMPLETED","sponsor":"University of Diyala","startDate":"2022-01-01","conditions":"Type 2 Diabetes","enrollment":80},{"nctId":"NCT02029846","phase":"PHASE4","title":"Glycemia in Diabetic Elders Trial","status":"TERMINATED","sponsor":"Johns Hopkins University","startDate":"2013-04","conditions":"Type 2 Diabetes Mellitus","enrollment":2},{"nctId":"NCT03871621","phase":"PHASE4","title":"Left Ventricular Functional Changes of Uncontrolled Diabetes by Dapagliflozin Treatment Trial","status":"COMPLETED","sponsor":"Mackay Memorial Hospital","startDate":"2019-04-01","conditions":"Type 2 Diabetes Mellitus","enrollment":76},{"nctId":"NCT02244164","phase":"NA","title":"Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.","status":"TERMINATED","sponsor":"Erasme University Hospital","startDate":"2014-10","conditions":"Type 2 Diabetes, Incretinomimetics, Pancreas","enrollment":5},{"nctId":"NCT04183868","phase":"PHASE4","title":"Effects of empagliFlozin on myocardIal metabOlic Rate of glucosE Estimated Through 18FDG PET (FIORE Study)","status":"COMPLETED","sponsor":"University of Catanzaro","startDate":"2016-04","conditions":"Type 2 Diabetes, Cardiovascular Risk Factor","enrollment":26},{"nctId":"NCT05641337","phase":"PHASE3","title":"Research on Optimal Strategy of Hypoglycemic Therapy for Cirrhosis With Diabetes","status":"UNKNOWN","sponsor":"Huashan Hospital","startDate":"2022-10-01","conditions":"Liver Cirrhosis, Diabetes","enrollment":184},{"nctId":"NCT05591235","phase":"PHASE3","title":"Effect of Metformin, Dapagliflozin, Combination of Metformin and Pioglitazone in Patients With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2022-11","conditions":"Type2diabetes, Insulin Resistance","enrollment":60},{"nctId":"NCT02446834","phase":"NA","title":"Research of Intensive Lifestyle Intervention for PCOS Patients With IGT","status":"COMPLETED","sponsor":"RenJi Hospital","startDate":"2015-04","conditions":"Polycystic Ovary Syndrome","enrollment":40},{"nctId":"NCT05545800","phase":"PHASE3","title":"Efficacy and Safety Of Different Regimens In Patients With Type 2 Diabetes Receiving Intensive Insulin Therapy","status":"UNKNOWN","sponsor":"Xiangya Hospital of Central South University","startDate":"2022-09-01","conditions":"Type 2 Diabetes Mellitus","enrollment":78},{"nctId":"NCT04700839","phase":"PHASE4","title":"SGLT2 Inhibitors in Patients With PCOS","status":"COMPLETED","sponsor":"Shanghai 10th People's Hospital","startDate":"2020-05-01","conditions":"Polycystic Ovary Syndrome","enrollment":68},{"nctId":"NCT05103306","phase":"","title":"Empagliflozin-based Quadruple Therapy vs Basal Insulin-based Therapy","status":"UNKNOWN","sponsor":"Chungbuk National University Hospital","startDate":"2017-01","conditions":"Diabetes Mellitus, Type 2","enrollment":300},{"nctId":"NCT03748810","phase":"","title":"Head-to-head Comparison of Empagliflozin and Dapagliflozin","status":"COMPLETED","sponsor":"Chungbuk National University Hospital","startDate":"2016-01-01","conditions":"Type2 Diabetes","enrollment":600},{"nctId":"NCT03798054","phase":"PHASE3","title":"Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-02-15","conditions":"Type 2 Diabetes Mellitus","enrollment":878},{"nctId":"NCT05214235","phase":"","title":"A Clinical Study on the Effect of Hypoglycemic Drugs on the Prognosis of Spinal Surgery in Diabetic Patients","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2022-02-07","conditions":"Diabetes Mellitus, Spinal Diseases","enrollment":124},{"nctId":"NCT05359341","phase":"NA","title":"Which is Better to Start With DPP-4 Inhibitors or SGLT-2 Inhibitors in Egyptian Diabetic Patients?","status":"COMPLETED","sponsor":"Sadat City University","startDate":"2020-09-20","conditions":"Diabete Type 2","enrollment":175},{"nctId":"NCT00580710","phase":"","title":"Investigation Into the Effects Upon Brain Response to Change in Circulating Glucose Levels in Diabetes Mellitus","status":"COMPLETED","sponsor":"Yale University","startDate":"2001-08","conditions":"Type 1 Diabetes, Hypoglycemia","enrollment":164},{"nctId":"NCT03958591","phase":"PHASE4","title":"Effects of Short-term Intensive De-escalation Therapy on Long-term Regimen Simplification","status":"UNKNOWN","sponsor":"Yanbing Li","startDate":"2019-05-01","conditions":"Diabetes type2","enrollment":274},{"nctId":"NCT02787551","phase":"PHASE3","title":"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-07-06","conditions":"Type 2 Diabetes Mellitus","enrollment":514},{"nctId":"NCT05262257","phase":"EARLY_PHASE1","title":"Evaluation and Intervention of Cognitive Function in Patients With Diabetes Mellitus.","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-04-01","conditions":"Type2 Diabetes","enrollment":120},{"nctId":"NCT04272359","phase":"","title":"Substitution of Sulfonylureas With New Generation of Hypoglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"University of Milan","startDate":"2019-05-06","conditions":"T2DM (Type 2 Diabetes Mellitus), Diet, Healthy, Renal Function Disorder","enrollment":138},{"nctId":"NCT04497792","phase":"PHASE4","title":"Safety and Efficacy of Empagliflozin for Patients With Diabetes Mellitus and Planned Percutaneous Coronary Interventions","status":"COMPLETED","sponsor":"Research Institute for Complex Problems of Cardiovascular Diseases, Russia","startDate":"2016-11","conditions":"Coronary Artery Disease, Diabetes Mellitus, Percutaneous Coronary Intervention","enrollment":40},{"nctId":"NCT05032001","phase":"NA","title":"ORAL ANTIDIABETICS EFFECT ON VISCERAL FAT","status":"UNKNOWN","sponsor":"Metabolic Research Unit","startDate":"2021-08-01","conditions":"Abdominal Obesity, Type 2 Diabetes","enrollment":30},{"nctId":"NCT04146155","phase":"PHASE4","title":"Efficacy and Safety of Liraglutide in Type 2 Diabetes With Lower Extremity Arterial Disease","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-05-01","conditions":"Type 2 Diabetes, Peripheral Vascular Disorder Due to Diabetes Mellitus","enrollment":200},{"nctId":"NCT04907708","phase":"NA","title":"Comparative Effects of Metformin and Insulin on Stereological Studies and Immunohistochemistry of Placenta","status":"COMPLETED","sponsor":"University of Karachi","startDate":"2018-01-01","conditions":"Diabetes Mellitus Arising in Pregnancy, Insulin-Requiring, Diabetes Mellitus in Pregnancy","enrollment":156},{"nctId":"NCT03285594","phase":"PHASE3","title":"Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents","status":"COMPLETED","sponsor":"Lexicon Pharmaceuticals","startDate":"2017-09-15","conditions":"Type 2 Diabetes Mellitus","enrollment":571},{"nctId":"NCT04879511","phase":"PHASE2, PHASE3","title":"Effect of Metformin in Children With Type 1 Diabetes","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2018-02-10","conditions":"Effect of Change in T1DM Glycemic Control","enrollment":80},{"nctId":"NCT04662866","phase":"PHASE2","title":"Effects of Glucose Lowering Agents in South Asian Women With Impaired Glucose Tolerance or Impaired Fasting Glucose","status":"UNKNOWN","sponsor":"Oslo University Hospital","startDate":"2021-02-10","conditions":"Impaired Glucose Tolerance, Insulin Sensitivity, Glucose Metabolism Disorders","enrollment":64},{"nctId":"NCT03751657","phase":"PHASE2","title":"A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2018-11-29","conditions":"Diabetes Mellitus, Type 2","enrollment":247},{"nctId":"NCT04192292","phase":"NA","title":"Study of Sulphonylurea Synergy With DPP4 Inhibitors","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2019-10-08","conditions":"Type 2 Diabetes","enrollment":30},{"nctId":"NCT02635386","phase":"PHASE3","title":"EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)","status":"COMPLETED","sponsor":"Woman's","startDate":"2016-03-22","conditions":"Polycystic Ovary Syndrome, Obesity","enrollment":119},{"nctId":"NCT02846233","phase":"NA","title":"Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2016-08","conditions":"Type 2 Diabetes Mellitus","enrollment":22},{"nctId":"NCT03711682","phase":"PHASE2, PHASE3","title":"Reducing Plasma Glucose Effect of Cinnamon in Type 2 Diabetic Patients in the Municipality of Comasagua","status":"COMPLETED","sponsor":"Universidad Dr. José Matías Delgado","startDate":"2018-03-01","conditions":"Type 2 Diabetes Mellitus","enrollment":30},{"nctId":"NCT03917758","phase":"NA","title":"Antidiuretic Function Before and During Treatment With SGLT2 Inhibitors","status":"UNKNOWN","sponsor":"University of Turin, Italy","startDate":"2018-10-10","conditions":"Diabetes Mellitus, Type 2, Arterial Hypertension, Body Weight Changes","enrollment":30},{"nctId":"NCT01213563","phase":"NA","title":"Management of Type 2 Diabetes After Gastric Bypass Surgery","status":"TERMINATED","sponsor":"Imperial College London","startDate":"2009-01","conditions":"Diabetes Mellitus, Type 2","enrollment":50},{"nctId":"NCT02730377","phase":"PHASE4","title":"Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-03-28","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":1991},{"nctId":"NCT02597049","phase":"PHASE3","title":"A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-11","conditions":"Type 2 Diabetes Mellitus","enrollment":424},{"nctId":"NCT04387630","phase":"PHASE2, PHASE3","title":"Neoadjuvant Chemotherapy With or Without Metformin in Early Breast Cancer.","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2020-06-05","conditions":"Breast Cancer","enrollment":120},{"nctId":"NCT03982238","phase":"PHASE4","title":"Effects of Hypoglycemic Drugs on Testosterone Levels in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"Majianhua","startDate":"2019-06-15","conditions":"Type 2 Diabetes","enrollment":74},{"nctId":"NCT03214380","phase":"PHASE3","title":"A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-07-14","conditions":"Type 2 Diabetes Mellitus","enrollment":933},{"nctId":"NCT04287387","phase":"PHASE4","title":"Response of Gut Microbiota in Type 2 Diabetes to Hypoglycemic Agents","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2020-03-02","conditions":"Type2 Diabetes Mellitus","enrollment":180},{"nctId":"NCT04237493","phase":"PHASE4","title":"Dosage Reduction and Acute Glycemic Complications in People With Type 2 Diabetes Who Fast During Ramadan","status":"COMPLETED","sponsor":"University of Jordan","startDate":"2017-02-14","conditions":"Diabetes Mellitus, Type 2","enrollment":687},{"nctId":"NCT02043054","phase":"PHASE3","title":"Effects of Liraglutide in Young Adults With Type 2 DIAbetes (LYDIA)","status":"COMPLETED","sponsor":"University of Leicester","startDate":"2013-12-16","conditions":"Type 2 Diabetes Mellitus, Cardiovascular Disease","enrollment":90},{"nctId":"NCT03850886","phase":"PHASE2","title":"Nicotinamide in Non-Alcoholic Fatty Liver Disease Patients","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2019-01-15","conditions":"Non Alcoholic Fatty Liver Disease","enrollment":61},{"nctId":"NCT03640221","phase":"PHASE4","title":"Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes.","status":"WITHDRAWN","sponsor":"Cedars-Sinai Medical Center","startDate":"2018-09-01","conditions":"Hypertension, Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT03577184","phase":"","title":"Evaluating the Glycemic Control wIth Vildagliptin and Metformin Combination Therapy.","status":"WITHDRAWN","sponsor":"Clinision","startDate":"2018-07","conditions":"Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT03813316","phase":"PHASE4","title":"Approaches To Therapy Escalation In T2D","status":"WITHDRAWN","sponsor":"LMC Diabetes & Endocrinology Ltd.","startDate":"2019-05-01","conditions":"Type2 Diabetes","enrollment":""},{"nctId":"NCT02752113","phase":"PHASE3","title":"Effects of Empagliflozin + Linagliptin vs Metformin + Insulin Glargine on Renal and Vascular Changes in Type 2 Diabetes","status":"COMPLETED","sponsor":"Institut für Pharmakologie und Präventive Medizin","startDate":"2016-04","conditions":"Diabetes Mellitus Type 2","enrollment":101},{"nctId":"NCT03983551","phase":"PHASE4","title":"Comparing the Renal Effect of Dipeptidyl-peptidase 4 Inhibitors and Sulfonylureas","status":"COMPLETED","sponsor":"Changhua Christian Hospital","startDate":"2016-03-01","conditions":"Type 2 Diabetes Mellitus, Proteinuria","enrollment":101},{"nctId":"NCT02954692","phase":"PHASE4","title":"A Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in Turkey","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-11-30","conditions":"Type 2 Diabetes Mellitus","enrollment":112},{"nctId":"NCT03204799","phase":"","title":"Metagenomic Analysis of Human Gut Microbiota in Patients With Metabolic Diseases Including Diabetes","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2016-12-17","conditions":"Type 2 Diabetes Mellitus, Dyslipidemias","enrollment":150},{"nctId":"NCT01841697","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-06-13","conditions":"Type 2 Diabetes","enrollment":642},{"nctId":"NCT01814748","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Omarigliptin (MK-3102) in ≥18 and <45 Year-Old Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK-3102-028)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-05-03","conditions":"Diabetes Mellitus","enrollment":203},{"nctId":"NCT02693392","phase":"NA","title":"Clinical Evaluation of Fenugreek Seed Extract, a Nutraceutical in Patients With Type- 2 Diabetes","status":"COMPLETED","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2016-01-17","conditions":"Type-2 Diabetes Mellitus","enrollment":200},{"nctId":"NCT02365233","phase":"PHASE4","title":"Fatty Liver Study in Patients With Type II Diabetes","status":"TERMINATED","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2013-05-01","conditions":"Type II Diabetes, Nonalcoholic Fatty Liver","enrollment":5},{"nctId":"NCT03078725","phase":"PHASE4","title":"Failure Rate of GLyburide And Metformin Among Gestational Diabetics","status":"WITHDRAWN","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2017-06-20","conditions":"Gestational Diabetes Mellitus, Class A2","enrollment":""}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"BLOOD POTASSIUM INCREASED"},{"count":1,"reaction":"DYSPNOEA"},{"count":1,"reaction":"OEDEMA"},{"count":1,"reaction":"RENAL FAILURE"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"hypoglycemic Agents(metformin)","genericName":"hypoglycemic Agents(metformin)","companyName":"First Affiliated Hospital of Wenzhou Medical University","companyId":"first-affiliated-hospital-of-wenzhou-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Metformin is a small molecule hypoglycemic agent used to treat Type 2 Diabetes Mellitus, as indicated by its study in various clinical trials on ClinicalTrials.gov. Its mechanism of action is not specified in the provided facts, but it is classified as a small molecule according to ChEMBL.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}